SCHEMBL1002900

SCHEMBL1002900

Cc1coc2cc3oc(=O)cc(C)c3cc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 1.00
KDM4E B2RXH2 7/20 1.00
HSD17B10 Q99714 5/20 0.68
HPGD P15428 5/20 0.68
TSHR P16473 3/20 0.68
POLB P06746 1/20 0.68
KCNA3 P22001 6/20 0.66
KCNA2 P16389 1/20 0.66
KCNA1 Q09470 1/20 0.66
CYP3A4 P08684 2/20 0.59
CYP1A2 P05177 2/20 0.59
CYP2C9 P11712 2/20 0.59
CYP2C19 P33261 2/20 0.59
CYP2D6 P10635 1/20 0.59
HTT P42858 1/20 0.59
NPSR1 Q6W5P4 1/20 0.59
MAOA P21397 3/20 0.58
THRB P10828 1/20 0.58
AKR1B1 P15121 1/20 0.58
MCL1 Q07820 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6995876 0.82 ALDH1A1 (0.78) ALDH1A1KDM4EHSD17B10HPGDTSHR
SCHEMBL19248241 0.82 ALDH1A1 (0.67) ALDH1A1KDM4EHSD17B10HPGDTSHR
SCHEMBL11380969 0.81 ALDH1A1 (1.00) ALDH1A1KDM4EHSD17B10HPGDTSHR
Hydrochloric Acid SCHEMBL7000338 0.81 ALDH1A1 (0.76) ALDH1A1KDM4EHSD17B10HPGDTSHR
SCHEMBL18074127 0.80 KCNA3 (0.79) ALDH1A1KDM4EHSD17B10HPGDTSHR
SCHEMBL18074006 0.80 KCNA3 (1.00) ALDH1A1KDM4EHSD17B10HPGDTSHR
SCHEMBL11376434 0.80 ALDH1A1 (0.68) ALDH1A1KDM4EHSD17B10HPGDTSHR
SCHEMBL18788580 0.78 KCNA3 (0.67) ALDH1A1KDM4EHSD17B10HPGDTSHR
4,6,7-Trimethyl-2H-Chromen-2-One SCHEMBL19049403 0.78 KDM4E (0.68) ALDH1A1KDM4EHSD17B10HPGDTSHR
SCHEMBL9120159 0.77 ALDH1A1 (0.63) ALDH1A1KDM4EHSD17B10HPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0579784-B1 METHOD FOR PREVENTING RESTENOSIS FOLLOWING RECONFIGURATION OF BODY VESSELS ADVANCED RES & TECH INST (US) 1999-11-10 EP claimed
EP-0579784-A4 1994-04-06 EP claimed
EP-0579784-A1 METHOD FOR PREVENTING RESTENOSIS FOLLOWING RECONFIGURATION OF BODY VESSELS INDIANA UNIVERSITY FOUNDATION (US) 1994-01-26 EP claimed
WO-1992018122-A1 METHOD FOR PREVENTING RESTENOSIS FOLLOWING RECONFIGURATION OF BODY VESSELS INDIANA UNIVERSITY FOUNDATION (US) 1992-10-29 WO claimed
US-5116864-A Method for preventing restenosis following reconfiguration of body vessels INDIANA UNIVERSITY FOUNDATION (US) 1992-05-26 US claimed
US-4950770-A Psoralens aminomethylation ELDER PHARMACEUTICALS, INC. (US) 1990-08-21 US claimed
US-4748120-A Photochemical decontamination treatment of whole blood or blood components DIAMOND SCIENTIFIC CO. (US) 1988-05-31 US claimed
WO-2023164075-A1 THERMOSTABLE UV INACTIVATED VACCINES AND OTHER BIOPHARMACEUTICALS UNIVERSAL STABILIZATION TECHNOLOGIES INC. (US) 2023-08-31 WO disclosed
US-20220168411-A1 PSORALEN-INACTIVATED CORONAVIRUS VACCINE AND METHOD OF PREPARATION THE UNITED STATES OF AMERICAN AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) 2022-06-02 US disclosed
US-20180169433-A1 METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS WITH PSORALEN DERIVATIVES IMMUNOLIGHT, LLC (US) 2018-06-21 US disclosed
US-20180169433-A1 METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS WITH PSORALEN DERIVATIVES IMMUNOLIGHT, LLC (US) 2018-06-21 US disclosed
US-20170113061-A1 METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS WITH PSORALEN DERIVATIVES IMMUNOLIGHT, LLC (US) 2017-04-27 US disclosed
US-20150291936-A1 PSORALEN-INACTIVATED DENGUE VIRUS VACCINE AND METHOD OF PREPARATION THE UNITED STATES OF AMERICAN AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) 2015-10-15 US disclosed
US-4727027-A FUROCOUMARIN DERIVATIVE AND ULTRAVIOLET IRRADIATION DIAMOND SCIENTIFIC CO. (US) 1988-02-23 US disclosed
US-4693981-A ULTRAVIOLET RADIATION AND FUROCOUMARIN ADVANCED GENETICS RESEARCH INSTITUTE (US) 1987-09-15 US disclosed
US-4556556-A ULTRAVIOLET INACTIVATION IN THE PRESENCE OF A FUROCOUMARIN COMPOUND ADVANCED GENETICS RESEARCH INSTITUTE (US) 1985-12-03 US disclosed
US-4545987-A Psoralen inactivated double-stranded RNA viral vaccines ADVANCED GENETICS RESEARCH INSTITUTE (US) 1985-10-08 US disclosed
EP-0124363-A2 Photochemical decontamination treatment of whole blood or blood components DIAMOND SCIENTIFIC CO. (US) 1984-11-07 EP disclosed
US-4298614-A 5'-Aminoalkyl-4',4-dialkylpsoralens THOMAS C. ELDER, INC. (US) 1981-11-03 US disclosed
US-4279922-A Photosensitizing benzofuranacrylics THOMAS C. ELDER, INC. (US) 1981-07-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170113061-A1 METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS WITH PSORALEN DERIVATIVES NFATC1, CDK10, CDK20 ALDH1A1 1790/4885KDM4E 655/4885HSD17B10 259/4885
US-20180169433-A1 METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS WITH PSORALEN DERIVATIVES NFATC1, CDK10, PDCD10 ALDH1A1 1556/4885KDM4E 948/4885HSD17B10 387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.